株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

遺伝子治療市場:世界の業界分析、規模、シェア、成長、動向、予測(2018~2026年)

Gene Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

発行 Transparency Market Research 商品コード 763025
出版日 ページ情報 英文 106 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
遺伝子治療市場:世界の業界分析、規模、シェア、成長、動向、予測(2018~2026年) Gene Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
出版日: 2018年10月31日 ページ情報: 英文 106 Pages
概要

当レポートでは、世界の遺伝子治療市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 序論

第2章 仮定と調査方法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
  • 市場分析と予測

第5章 市場見通し

第6章 製品別市場分析と予測

  • イントロダクション・定義
  • 主な調査結果/動向
  • 市場価値予測
    • Yescarta
    • Kymriah
    • Luxturna
    • Strimvelis
    • Gendicine
  • 市場の魅力度

第7章 用途別市場分析と予測

  • イントロダクション・定義
  • 主な調査結果/動向
  • 市場価値予測
    • 眼科
    • 腫瘍科
    • アデノシン脱アミノ酵素
  • 市場の魅力度

第8章 米国市場

第9章 欧州市場

第10章 その他の諸国市場

第11章 競合環境

  • 市場参入者:競合マトリクス
  • 市場シェア分析
  • 企業プロファイル
図表

List of Tables

  • Table 01: Pipeline Analysis: Gene therapy Candidates (1/8)
  • Table 02: Pipeline Analysis: Gene therapy Candidates (2/8)
  • Table 03: Pipeline Analysis: Gene therapy Candidates (3/8)
  • Table 04: Pipeline Analysis: Gene therapy Candidates (4/8)
  • Table 05: Pipeline Analysis: Gene therapy Candidates (5/8)
  • Table 06: Pipeline Analysis: Gene therapy Candidates (6/8)
  • Table 07: Pipeline Analysis: Gene therapy Candidates (7/8)
  • Table 08: Pipeline Analysis: Gene therapy Candidates (8/8)
  • Table 09: Global Gene Therapy Market Size (US$ Mn) Forecast, by Type, 2017-2026
  • Table 10: Global Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017-2026
  • Table 11: U.S. Gene Therapy Market Size (U.S.$ Mn) Forecast, by Product, 2017-2026
  • Table 12: U.S. Gene Therapy Market Size (U.S.$ Mn) Forecast, by Application, 2017-2026
  • Table 13: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2017-2026
  • Table 14: Europe Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017-2026
  • Table 15: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Product, 2017-2026
  • Table 16: Rest of the World Gene Therapy Market Size (US$ Mn) Forecast, by Application, 2017-2026

List of Figures

  • Figure 01: Market Segmentation: Global Gene Therapy Market
  • Figure 02: Research Methodology: Global Gene Therapy Market
  • Figure 03: Analysis by Product
  • Figure 04: Analysis by Application
  • Figure 05: Analysis by Region
  • Figure 06: Key Industry Developments
  • Figure 07: Drivers and Restraints: Global Gene Therapy Market
  • Figure 08: Global Gene Therapy Market Value (US$ Mn) Forecast, 2017-2026
  • Figure 09: Global Gene Therapy Market Value Share, by Product (2017)
  • Figure 10: Global Gene Therapy Market Value Share, by Application (2017)
  • Figure 11: Global Gene Therapy Market Value Share, by Country/Region (2017)
  • Figure 12: Key Findings: Global Gene Therapy Market, by Product
  • Figure 13: Introduction: Global Gene Therapy Market, by Product
  • Figure 14: Global Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 15: Global Gene Therapy Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 16: Global Gene Therapy Market Revenue (US$ Mn), by Yescarta, 2017-2026
  • Figure 17: Global Gene Therapy Market Revenue (US$ Mn), by Kymriah, 2017-2026
  • Figure 18: Global Gene Therapy Market Revenue (US$ Mn), by Luxturna, 2017-2026
  • Figure 19: Global Gene Therapy Market Revenue (US$ Mn), by Strimvelis, 2017-2026
  • Figure 20: Global Gene Therapy Market Revenue (US$ Mn), by Gendicine, 2017-2026
  • Figure 21: Key Findings: Global Gene Therapy Market, by Application
  • Figure 22: Introduction: Global Gene Therapy Market, by Application
  • Figure 23: Global Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 24: Global Gene Therapy Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 25: Global Gene Therapy Market Revenue (US$ Mn), by Ophthalmology, 2017-2026
  • Figure 26: Global Gene Therapy Market Revenue (US$ Mn), by Oncology, 2017-2026
  • Figure 27: Global Gene Therapy Market Revenue (US$ Mn), by ADA-SCID, 2017-2026
  • Figure 28: U.S. Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 29: U.S. Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 30: U.S. Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 31: U.S. Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 32: U.S. Gene Therapy Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 33: Europe Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 34: Europe Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 35: Europe Gene Therapy Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 36: Europe Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 37: Europe Gene Therapy Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 38: Rest of the World Gene Therapy Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 39: Rest of the World Gene Therapy Market Value Share Analysis, by Product, 2017 and 2026
  • Figure 40: Rest of the World Gene Therapy Market Attractiveness Analysis, by Product, 2018-2026
  • Figure 41: Rest of the World Gene Therapy Market Value Share Analysis, by Application, 2017 and 2026
  • Figure 42: Rest of the World Gene Therapy Market Attractiveness Analysis, by Application, 2018-2026
  • Figure 43: Competition Matrix: Global Gene Therapy Market
  • Figure 44: Novartis AG, Company Details
  • Figure 45: Novartis AG, Product Portfolio
  • Figure 46: Novartis AG, Breakdown of Net Sales, by Geography (2017)
  • Figure 47: Novartis AG, Breakdown of Net Sales, by Business Segment (2017)
  • Figure 48: Novartis AG, Revenue (US$ Bn) & Y-o-Y Growth (%), 2015-2017
  • Figure 49: Novartis AG, R&D Intensity and Sales & Marketing Intensity - Company Level, 2016-2017
  • Figure 50: Novartis AG, SWOT Analysis
  • Figure 51: Orchard Therapeutics Limited, Company Details
  • Figure 52: Orchard Therapeutics Limited, Product Portfolio
  • Figure 53: Orchard Therapeutics Limited, SWOT Analysis
  • Figure 54: CELGENE CORPORATION, Company Details
  • Figure 55: CELGENE CORPORATION, Product Portfolio
  • Figure 56: CELGENE CORPORATION, Revenue (US$ Bn) & Y-o-Y Growth (%), 2014-2017
  • Figure 57: CELGENE CORPORATION, Breakdown of Net Sales, by Key Products (2017)
  • Figure 58: CELGENE CORPORATION, Breakdown of Net Sales, by Geography (2017)
  • Figure 59: CELGENE CORPORATION, R&D Intensity and Sales & Marketing Intensity: Company Level, 2016-2017
  • Figure 60: CELGENE CORPORATION, SWOT Analysis
  • Figure 61: Spark Therapeutics, Inc., Company Details
  • Figure 62: Spark Therapeutics, Inc., Product Portfolio
  • Figure 63: Spark Therapeutics, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2015-2017
  • Figure 64: Spark Therapeutics, Inc., R&D Expenditure, 2016-2017
  • Figure 65: Spark Therapeutics, Inc., SWOT Analysis
  • Figure 66: Gilead Sciences, Inc., Company Details
  • Figure 67: Gilead Sciences, Inc., Product Portfolio
  • Figure 68: Gilead Sciences, Inc., Revenue (US$ Bn) & Y-o-Y Growth (%), 2015-2017
  • Figure 69: Gilead Sciences, Inc., R&D Expenditure (US$ Bn), 2016-2017
  • Figure 70: Gilead Sciences, Inc., SWOT Analysis
  • Figure 71: Sibiono GeneTech Co. Ltd, Company Details
  • Figure 72: Sibiono GeneTech Co. Ltd, Product Portfolio
  • Figure 73: Sibiono GeneTech Co. Ltd, SWOT Analysis
目次

Title:
Gene Therapy Market (Product - Yescarta, Kymriah, Luxturna, Strimvelis, Gendicine; Application - Ophthalmology, Oncology, Adenosine Deaminase Deficient Severe Combined Immunodeficiency (ADA-SCID)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Gene Therapy Market - Overview

This report studies the current as well as future prospects of the global gene therapy market. Stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, and provision of gene therapy products and new entrants planning to enter the market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. This section also provides the overall information and data analysis of the global gene therapy market regarding leading segments based on product, application, and region.

The global gene therapy market has been segmented based on product, application, and region. In terms of product, the global market has been classified into Yescarta, Kymriah, Luxturna, Strimvelis, and Gendicine. In terms of application, the global market has been divided into ophthalmology, oncology, and adenosine deaminase?deficient severe combined immunodeficiency (ADA-SCID).

The market revenue for each product was estimated using bottom-up approach. The revenue generated by each product and application has been calculated considering marketing approvals of the products, sales, number of patients treated, cost of products, and pattern in different regions. The bottom-up approach for determining the country market size was studied using various market indicators obtained from secondary sources, which include different products and their applications and their cost variations in major country/region, prevalence and incidence in major countries for eligible patients with relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), acute lymphoblastic leukemia (ALL), acute lymphoblastic leukemia (ALL) and head and neck cancer. Revenues of all publicly listed market players were obtained through secondary sources and analyzed for gene therapy specific revenues by narrowing down to revenue percentage for product segment through extensive secondary analysis of annual reports, investor presentations, press releases, primary interviews, and others. Data triangulation is based on secondary research (top-down and bottom-up approaches) and primary research. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2017 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The market overview section of the report explores market dynamics such as drivers, restraints, opportunities, and key trends that have a strong impact on the gene therapy market and could influence it in the near future. Market attractiveness analysis has been provided to explain the intensity of competition across different regions. The competitive scenario among different players is evaluated through market share analysis in the competitive landscape section of the report. These factors are likely to help market players take strategic decisions to strengthen their positions and expand their shares in the global gene therapy market.

In terms of region, the global gene therapy market has been segmented into the U.S., Europe, and rest of world. The market size and forecast for each of these regions has been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the overview section. This section of the report also provides the market attractiveness analysis and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global gene therapy market.

Major players operating in the global gene therapy market include Gilead Sciences, Inc., Novartis AG, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., CELGENE CORPORATION, and Orchard Therapeutics Limited.

The global gene therapy market has been segmented as follows:

Global Gene Therapy Market, by Product

  • Yescarta
  • Kymriah
  • Luxturna
  • Strimvelis
  • Gendicine

Global Gene Therapy Market, by Application

  • Ophthalmology
  • Oncology
  • Adenosine Deaminase-Deficient Severe Combined Immunodeficiency (ADA-SCID)

Global Gene Therapy Market, by Region

  • U.S.
  • Europe
  • Rest of World

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives

2. Assumptions and Research Methodology

3. Executive Summary : Global Gene Therapy Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Gene Therapy Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Gene Therapy Market Analysis and Forecasts, 2017-2026

5. Market Outlook

  • 5.1.Clinical Trial Pipeline Analysis

6. Global Gene Therapy Market Analysis and Forecasts, by Product

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Global Gene Therapy Market Value Forecast, by Product, 2017-2026
    • 6.3.1. Yescarta
    • 6.3.2. Kymriah
    • 6.3.3. Luxturna
    • 6.3.4. Strimvelis
    • 6.3.5. Gendicine
  • 6.4. Market Attractiveness, by Product

7. Global Gene Therapy Market Analysis and Forecasts, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Global Gene Therapy Market Value Forecast, by Application, 2017-2026
    • 7.3.1. Ophthalmology
    • 7.3.2. Oncology
    • 7.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
  • 7.4. Global Gene Therapy Market Attractiveness, by Application

8. U.S. Gene Therapy Market Analysis and Forecast

  • 8.1. Introduction
  • 8.2. U.S. Gene Therapy Market Value Forecast, by Product, 2017-2026
    • 8.2.1. Yescarta
    • 8.2.2. Kymriah
    • 8.2.3. Luxturna
    • 8.2.4. Strimvelis
    • 8.2.5. Gendicine
  • 8.3. U.S. Gene Therapy Market Value Forecast, by Application, 2017-2026
    • 7.3.1. Ophthalmology
    • 7.3.2. Oncology
    • 7.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
  • 8.4. U.S. Gene Therapy Market Attractiveness Analysis
    • 8.4.1. By Product
    • 8.4.2. By Application

9. Europe Gene Therapy Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Europe Gene Therapy Market Value Forecast, by Product, 2017-2026
    • 9.2.1. Yescarta
    • 9.2.2. Kymriah
    • 9.2.3. Luxturna
    • 9.2.4. Strimvelis
    • 9.2.5. Gendicine
  • 9.3. Europe Gene Therapy Market Value Forecast, by Application, 2017-2026
    • 9.3.1. Ophthalmology
    • 9.3.2. Oncology
    • 9.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
  • 9.4. Europe Gene Therapy Market Attractiveness Analysis
    • 9.4.1. By Product
    • 9.4.2. By Application

10. Rest of World Gene Therapy Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Rest of World Gene Therapy Market Value Forecast, by Product, 2017-2026
    • 10.2.1. Yescarta
    • 10.2.2. Kymriah
    • 10.2.3. Luxturna
    • 10.2.4. Strimvelis
    • 10.2.5. Gendicine
  • 10.3. Rest of World Gene Therapy Market Value Forecast, by Application, 2017-2026
    • 10.3.1. Ophthalmology
    • 10.3.2. Oncology
    • 10.3.3. Adenosine Deaminase?Deficient Severe Combined Immunodeficiency (ADA-SCID)
  • 10.4. Rest of World Gene Therapy Market Attractiveness Analysis
    • 10.4.1. By Product
    • 10.4.2. By Application

11. Competition Landscape

  • 11.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 11.2.Market Share Analysis, by Company (2017)
  • 11.3. Company Profiles
    • 11.3.1. Novartis AG
  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview
  • Financial Overview
    • 11.3.2. Orchard Therapeutics Limited.
  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview
    • 11.3.3. CELGENE CORPORATION
  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview
    • 11.3.4. Spark Therapeutics, Inc.
  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview
    • 11.3.5. Gilead Sciences, Inc.
  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview
    • 11.3.6. Sibiono GeneTech Co. Ltd.

Company Overview (HQ, Business Segments, Employee Strength)

  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview
Back to Top